Regeneron and Sanofi's COPD Drug Shows Mixed Results in Phase 3 Trials
TL;DR Summary
A key Phase 3 trial of Regeneron and Sanofi's COPD drug, itepekimab, failed to meet its primary endpoint, causing a significant drop in their stock prices, although one of the two trials showed a meaningful benefit. The companies are reviewing the data and consulting with regulators to determine next steps.
- COPD Drug Developed by Regeneron, Sanofi Fails Key Test Investopedia
- Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies GlobeNewswire
- Regeneron Stock Plunges. Why a Drug Trial Missed the Mark. Barron's
- Sanofi, Regeneron Respiratory Drug Delivers Mixed Results in Key Trials WSJ
- Next-gen COPD drug from Sanofi, Regeneron shows mixed results in Phase 3 trials statnews.com
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
1 min
vs 2 min read
Condensed
83%
290 → 50 words
Want the full story? Read the original article
Read on Investopedia